Live event: Wednesday 14th June 2017
07:00 [PDT] 10:00 [EDT] 15:00 [BST]
Not your time zone? Please find the conversion here.
The objective of this study was to evaluate disease stage-associated differences in receptor tyrosine kinase (RTK) signaling in A549 cells using pretreatment sera from cases of pathologically-confirmed lung adenocarcinoma at various stage of disease progression or control cases derived from a lung cancer screening study. This was accomplished as a means to explore the hypothesis that circulating concentrations of decoy receptors and/or ligands, as well as disease-specific ligand degradation all regulate RTK signaling in vivo.
What will you learn?
- Hear about recent research on tyrosine kinase signaling in patients with lung adenocarcinoma
- Associations of circulating biomarker levels with disease progression in lung cancer
- Results from the evaluation of the matching patient sera to stimulate RTK signaling
- Discuss potential mechanisms leading to disparity in these findings
- Gain insight into how to successfully integrate multiplexed immunoassays into your cancer research workflow
- Learn about best practices for running multiplex protein detection assays to generate the highest quality data
Who may this interest?
- Cancer researchers
- Companies who focus on cancer research (small molecules, mAbs, ADC, cell therapies, BiSpmAbs)
Dr. Jeffrey A. Borgia
Departments of Pathology, Department of Cell and Molecular Medicine
Rush University Medical Center
Dr. Jeffrey A. Borgia is an Associate Professor at Rush University Medical Center in Chicago, IL, in the Departments of Pathology and the Department of Cell and Molecular Medicine, and has been at Rush for 15 years. Dr. Borgia also holds the positions of Director of the Rush Biomarker Development Core as well as the Rush Translational Cancer Research Graduate Program. His research is focused on developing novel “-omics” diagnostic tests for profiling patient specimens and providing mechanistic insights for pathophysiology. Dr. Borgia oversees the collection and annotation of patient specimens for translational research projects and ongoing clinical trials at the Rush University Cancer Center. Additionally, at the Core, he and his team work on discovery and development of new/novel biomarkers for use in diagnostics.
Dr. Wen-Rong Lie
Dr. Wen-Rong Lie is a Principal Scientist at MilliporeSigma and has been working on biomarker immunoassay development there for 13 years. She has developed multiplex protein immunoassay panels for studying skin and bone metabolism, angiogenesis, neurodegenerative diseases, cell signaling pathways, immunology and oncology. Her current work is focused on developing new biomarker assay tools for immuno-oncology research and cancer autoantibody profiling. Dr. Lie has also worked with researchers in academia and pharma to develop custom biomarker panels and to advance science through research collaboration. Before joining MilliporeSigma, Dr. Lie worked for 12 years in pharma drug discovery R&D in Immunology and Oncology at Searle/Pharmacia/Pfizer.
If you are interested in viewing other Oncology Central webinars, please find our other events listed here.